Linezolid
- Generic Name
- Linezolid
- Brand Names
- Zyvox, Zyvoxam
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20FN3O4
- CAS Number
- 165800-03-3
- Unique Ingredient Identifier
- ISQ9I6J12J
- Background
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...
- Indication
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...
- Associated Conditions
- Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
- Associated Therapies
- -
Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 248
- Registration Number
- NCT06709196
- Locations
- 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Urology, Rigshospitalet, Copenhagen, Denmark
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06649721
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China
🇨🇳The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Model-informed Precision Dosing for Linezolid
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- University of Hamburg-Eppendorf
- Target Recruit Count
- 28
- Registration Number
- NCT06444802
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 690
- Registration Number
- NCT06441006
- Locations
- 🇲🇩
Institute of Phthisiopneumology Chiril Dragniuc, Chisinau, Moldova, Republic of
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
🇵🇪Hospital Nacional Hipólito Unanue, Lima, Peru
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Target Recruit Count
- 1000
- Registration Number
- NCT06126263
- Locations
- 🇺🇸
National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda, Maryland, United States
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 300
- Registration Number
- NCT06058299
- Locations
- 🇵🇭
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵🇭Tropical Disease Foundation, Makati City, Philippines
Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 140
- Registration Number
- NCT05813951
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.